Geneva [Switzerland], November 3 (ANI): The World Health Organisation (WHO) has said that Covaxin — COVID-19 vaccine developed by Bharata Biotech — is extremely suitable for low and middle-income countries due to easy storage requirements.
The UN health body — which granted approval for Emergency Use Listing (EUL) of Covaxin on Wednesday — said that the Bharat Biotech’s vaccine was found to have 78 per cent efficacy against the COVID-19 of any severity, 14 or more days after the second dose. “Covaxin was found to have 78 per cent efficacy against COVID19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements,” WHO said in a tweet on Wednesday.
The UN health body’s emergency use listing procedure assess the vaccine under the procedure based on the review of data on quality, safety, efficacy, a risk management plan and suitability in low- and middle-income countries.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single-dose vials and multidose vials of 5, 10 and 20 doses.
Dr Poonam Khetrapal Singh, WHO’s South-East Asia Regional Director, has congratulated India on the emergency use listing of Bharat Biotech’s COVID-19 vaccine Covaxin on Wednesday.
“Congratulations India for Emergency Use Listing of its indigenously produced COVID19 vaccine COVAXIN,” said Dr Singh in a tweet.
The WHO panel had earlier sought additional clarifications from the manufacturer of Covaxin, in order to conduct a final EUL risk-benefit assessment for global use of the vaccine.
The approval was done on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL), an independent advisory panel that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure. (ANI)